Orphan Reach   Report issue

For profit Phase 2 Phase 3
Founded: Milton Keynes United Kingdom (2004)
Status: Acquired by The EMMES Corporation (2021)

Organization Overview

First Clinical Trial
2015
NCT02452931
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Orphan Reach

Active Ingredients

Drugs in Phase 3 Trials (1)

leuprolide (lupron) (1 trial)

Drugs in Phase 2 Trials (1)

c21 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fibrosis (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 2)

Puberty, Precocious (Phase 3)

Pulmonary Fibrosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2